SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs after-hours selloff was widely discussed alongside the FAAs nationwide ground stop over air-traffic communications problems, with traders speculating about a cyberattack while others viewed it as a technical failure and the market reaction as overblown. The debate came amid broader pressure on AI and semiconductor stocks, with traders split between expecting more downside and buying a rebound.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention ahead of the FDA decision on ivonescimab for EGFR-mutated lung cancer, with traders focused on whether the drug can win approval despite missing formal statistical significance on the trials overall-survival endpoint. The debate is sharply split: bears point to the FDAs stated OS requirement and see CRL risk, while bulls cite the strong progression-free-survival result, favorable later survival trends, and AstraZenecas investment.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

A nationwide FAA ground stop tied to an air-traffic-control communications issue is drawing attention to AAL and other airlines, with traders reacting to possible flight delays and the sectors modest decline. Speculation about a cyberattack appears in the discussion, but the cause has not been confirmed.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop for departing flights has put airline stocks, including Delta, in focus; traders cite safety-related operational disruption, while speculation about air-traffic communications failures remains unconfirmed. The community is split between expecting a negative impact and noting that DALs share price has reacted only modestly.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss post-earnings outlook has focused attention on delays activating third-party data-center capacity, which pushed expected revenue into later periods and prompted analyst target cuts. Traders are sharply divided: bears see execution and valuation risks amid a broader AI/neocloud selloff, while bulls view the delays as temporary and argue demand remains strong.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

A reported FAA nationwide ground stop ordering departing U.S. flights to remain grounded is drawing attention to UAL and other airlines. Traders are reacting with alarm, while speculation about communications failures or other causes remains unconfirmed.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

NTLAs sharp slide is drawing debate, with many traders attributing it to short selling and stop-loss liquidations, while others point to a broader selloff in speculative small-cap biotech amid rising yields and weak bids. The discussion also weighs the decline against lonvo-zs reported HAE data and pending FDA review, with bears questioning the companys commercial prospects; no new company catalyst clearly explains the drop.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians persistent share-price weakness and failed rebounds dominate discussion, with traders blaming short pressure or broader EV-sector weakness while others say there is no clear company-specific trigger. Bulls point to the R2 rollout and upcoming Autonomy & AI Day as potential catalysts; bears remain focused on cash burn and dilution concerns.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

Traders are speculating that the FAAs nationwide ground stop, attributed to a communications issue, could have a cyber angle and boost cybersecurity stocks. The community is debating that potential upside, but no cyberattack has been confirmed.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Anticipation of Phase 3 REGAL topline results for SELLASs GPS leukemia treatment is driving attention, with bullish traders expecting a major catalyst and skeptics emphasizing the trials binary risk. Sharp swings in the shares have also fueled disagreement over whether selling reflects ordinary profit-taking or alleged short-term market pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABSI Could reach the moon with this one

• Uses generative AI to discover and develop drugs faster and potentially cheaper than traditional methods.

• Eli Lilly invested $40M, providing major pharmaceutical validation.

• ABS-201 targets the multibillion-dollar hair loss market, with encouraging early clinical results.

• Potential expansion into endometriosis opens another massive market.

• $201M in cash and investments as of Q2, with funding expected into late 2028.

• Major clinical catalysts ahead in late 2026 and early 2027.

The opportunity: If ABS-201 succeeds, Absci could transition from a speculative AI biotech into a valuable commercial drug developer. High risk, but significant upside potential.

I also want in before funds start pouring money into healthcare focused on AI. $IAM and $GENB are also candidates found in my portfolio. Do some due diligence, cause there might be big money to be made here. 🎯

Highbank

Jack Tamura

StockTwits for iOS

Justin F

Absci Corp

Iambic Therapeutics Inc.

Generate Biomedicines Inc

 Could reach the moon with this one

• Uses generative AI to discover and develop drugs faster and potentially cheaper than traditional methods.

• Eli Lilly invested $40M, providing major pharmaceutical validation.

• ABS-201 targets the multibillion-dollar hair loss market, with encouraging early clinical results.

• Potential expansion into endometriosis opens another massive market.

• $201M in cash and investments as of Q2, with funding expected into late 2028.

• Major clinical catalysts ahead in late 2026 and early 2027.

The opportunity: If ABS-201 succeeds, Absci could transition from a speculative AI biotech into a valuable commercial drug developer. High risk, but significant upside potential.

I also want in before funds start pouring money into healthcare focused on AI. 

 are also candidates found in my portfolio. Do some due diligence, cause there might be big money to be made here. 🎯